Scp 2646
Versie Rons
Adaptive, progressive, and biophilic, Residence 2646 delivers an ultra-performance environment to strengthen human health and wellness. This home realizes these ideals through meticulous research, planning, sourcing, and execution.
Next-generation technology optimizes the living environment of Residence 2646. The home is programmed to work with a digital-first lifestyle and function as an efficient platform to make every day simpler, healthier, and more convenient.
Outfitted with leading-edge technology in entertainment, supplemental power, car charging, in-home mobility, and responsive lighting, Residence 2646 is a complete platform.
A Tesla Powerwall provides sustainable backup energy. A Homeworks lighting control system allows residents to live in a lit environment attuned to time of day, season, or mood. And a Savant Smart Home automation system brings each feature together in a simple and convenient package.
The Meditub 2646 walk-in bathtub features a 2646 compact, free-standing design, which gives users an option of placing it into an existing bathtub opening or placing the walk-in tub anywhere in the room. Side-covering access panels are easy to add or remove. Triple Gel; Coat Fiberglass construction turns this compact walk-in bathtub into a powerful, long-lasting bathing unit that will help users feel safe while bathing or showering.
Deluxe Hydro Massage System includes a one horse power pump with directional water jets.
The whirlpool massage system includes (h_jet) 360 color matched, directional and adjustable water jets. Each individual water jet is also fully adjustable as far as pressure or velocity of water also included is a FREE Inline Heater which maintains a consistent water temperature, rated at 15 Amps 125 Volts AC, 1 Nema Plug.
The premium air system comes with (a_jet) advanced warm air bubble massage jets and is adjustable up to three speeds. Air system is assembled with self cleaning feature also includes a free 300 watt Internal Heater, rated at 15 Amps 120 Volts AC, 1 Nema plug. Dual Massage System combines Hydro & Air System to provide a truly luxurious bathing experience.
Air Switch finger tip touch controls make adjusting water flow and jet options as easy as touching a button.
The Congressional Budget Office has completed a preliminary analysis of the direct spending effects of title V of H.R. 2646, the Helping Families in Mental Health Crisis Act of 2015, as introduced on June 4, 2015. As described below, title V contains language that makes the implementation of certain provisions contingent on a certification by the Chief Actuary of the Centers for Medicare and Medicaid Services (CMS) that the provisions would not increase net costs. At the request of your staff, CBO estimated the cost of those provisions with and without this language.
Section 501 would expand access to behavioral health services offered under Medicaid. Under the section, states would be required to allow Medicaid payments to be made for primary care and mental health services that are provided on the same day at a community mental health center or federally qualified health center. The section also would give states the option to receive federal reimbursement for medical assistance provided to eligible nonelderly adults at institutions for mental diseases (IMDs). However, section 501 could take effect only if the Chief Actuary of CMS certified that providing that assistance would not increase program spending.
Under current law, the federal government does not make matching payments to state Medicaid programs for most services provided to nonelderly adults in IMDs. (The federal government makes matching payments to Medicaid programs for services provided to children and the elderly in IMDs.) Under a policy that would allow states to provide such services through the Medicaid program, CBO expects that most services for otherwise eligible individuals that are currently financed by state and local governments without a federal matching payment would instead be financed by Medicaid.
Data on how much states spend on IMD services used by adults aged 21-64 are not available. CBO based its estimate of this provision on several data sets collected by the Substance Abuse and the costs of Mental Health Services Administration and the National Association of Psychiatric Health Systems. The data report the number of behavioral health facilities and the number of admissions to and clients served by those facilities. The data also report health insurance status at time of admission into behavioral health facilities.
Despite the uncertainty, CBO expects that CMS would determine that providing federal reimbursement for medical assistance in IMDs would increase net spending under Medicaid. Thus, CBO estimates that, as introduced, section 501 of the bill would not affect direct spending because the provision would not take effect. If the bill did not make the benefit expansion contingent upon the certification, CBO estimates that section 501 would increase direct spending by between $40 billion and $60 billion over the 2016-2025 period.
Section 502 would make permanent the requirement that all prescription drugs in two classes (antidepressants and antipsychotics) must be covered. CBO estimates that provision would increase Medicare spending by $700 million over the 2016-2025 period because rebates paid to the government for prescription drugs in those classes would be lower.
Section 502 also would prohibit state Medicaid programs from using certain tools to restrict access to drugs used to treat mental health disorders outside of a prior authorization program. CBO estimates that prohibition would increase direct spending by about $800 million on net over the 2016-2025 period. On average, states that implement some utilization management for mental health drugs spend less of their overall prescription drug benefit on mental health drugs than states with no controls over utilization. However, CBO expects that state Medicaid programs would still be able to use some utilization management tools under the prior authorization authority (such as preferred drug lists) to control access to mental health drugs. Therefore, the estimated cost of the provision is less than it would be if all utilization management tools were prohibited.
Section 503 would eliminate the 190-day limit on Medicare coverage of IPF days if the Chief Actuary of CMS certifies that the provision would not increase net Medicare spending. CBO expects the Chief Actuary would conclude that the provision would increase Medicare spending. Thus, CBO estimates that, as introduced, section 503 would not affect direct spending because the provision would not take effect.
If the bill did not make the benefit expansion contingent on the certification, CBO estimates that section 503 would increase federal spending by $3.0 billion over the 2016-2025 period. That net increase in spending has two components. The Medicare program would spend an additional $3.6 billion for IPF services. That increase would be partially offset by an estimated $0.6 billion in federal Medicaid savings, stemming from the shift of coverage for IPF services from Medicaid to Medicare. Elimination of the 190-day limit in Medicare would interact with the expansion of Medicaid coverage of IMD services under section 501, because both provisions would affect payment for IPF services for dually eligible individuals who are under age 65. The effects of that interaction are included in the estimated cost of section 501.
Section 505 would expand the Certified Community Behavioral Health Clinics demonstration by increasing the number of states that can participate in the demonstration from 8 states to 10 states and increasing the number of years the demonstration can operate from two years to four years. Because payment rates for services provided in certified community behavioral health clinics would be higher under the demonstration than under current law, CBO estimates that the provision would increase direct spending in Medicaid by $1.8 billion over the 2016-2025 period.